Integrated Genetics and MRD Guide Transplant in Ph-Negative ALL

A prospective study shows that combining genetic risk with early molecular response identifies adults who can safely avoid transplantation.

For Doctors in a Hurry

Clinicians lack a uniform method for combining genetic risk and measurable residual disease to guide consolidation therapy in adult leukemia.
This study evaluated 436 adults with Philadelphia chromosome-negative acute lymphoblastic leukemia using risk-stratified treatment based on genetics and residual disease.
Patients with low genetic risk and negative residual disease achieved 81% survival, while those with high-risk genetics reached 50%.
The researchers concluded that integrating genetic markers with measurable residual disease accurately identifies candidates for stem cell transplantation or chemotherapy.
These findings suggest that genetic risk factors significantly influence outcomes even when patients achieve negative measurable residual disease status.

Refining Risk Stratification in Adult Acute Lymphoblastic Leukemia

The management of adult Philadelphia chromosome-negative acute lymphoblastic leukemia has shifted toward pediatric-inspired protocols that emphasize intensive induction and risk-adapted consolidation [1, 2]. While achieving measurable residual disease negativity is a primary driver of long-term survival, relying solely on early molecular response may overlook patients with high-risk genetic profiles who remain prone to late relapse [3, 4]. Recent advances in immunotherapy, such as the bispecific T-cell engager blinatumomab, have improved outcomes by inducing deeper remissions, yet the optimal criteria for transitioning patients to allogeneic hematopoietic stem cell transplantation remain debated [5, 6]. Clinicians must balance the curative potential of transplantation against significant treatment-related mortality, particularly in older adults [7, 8]. A prospective study now evaluates an integrated model that combines centralized genetic assessment with early measurable residual disease kinetics to refine therapy allocation, offering a clearer roadmap for deciding which patients truly need a transplant.

Defining High Genetic Risk and Treatment Allocation

The study utilized a rigorous framework to determine which patients required an allogeneic hematopoietic stem cell transplant versus those who could safely proceed with chemotherapy alone. Researchers assigned patients to transplant if they met any of three primary criteria: the presence of high genetic risk features, the requirement of two induction cycles to achieve complete remission, or the detection of measurable residual disease (the presence of subclinical leukemia cells) at a threshold of 0.01% or higher at the end of induction. Conversely, patients who achieved complete remission after a single induction cycle, lacked high-risk genetic markers, and maintained an end-of-induction measurable residual disease level below 0.01% were assigned to a less intensive path of delayed consolidation and maintenance chemotherapy. The definition of high genetic risk was lineage-specific and incorporated both molecular markers and clinical variables. For patients with B-lineage acute lymphoblastic leukemia, high genetic risk included the presence of KMT2A rearrangements, low hypodiploidy (a chromosomal abnormality characterized by fewer than 40 chromosomes that confers a poor prognosis), or an age greater than 35 years. Additionally, researchers categorized these patients as high risk if they exhibited homozygous TP53 mutations or deletions, or if they possessed concomitant deletions in both the IKZF1 and CDKN2A/B genes. Risk stratification for T-lineage acute lymphoblastic leukemia relied on a different set of molecular indicators. Patients were classified as high risk if they lacked mutations in NOTCH1 or FBXW7, or if they harbored alterations in the K/NRAS or PTEN genes. A distinct subset of patients with early T-cell precursor acute lymphoblastic leukemia (a high-risk subtype characterized by an immunophenotype reflecting early thymic progenitors) followed a separate clinical track. These early T-cell precursor patients received a different induction regimen and were all assigned to receive an allogeneic hematopoietic stem cell transplant regardless of their initial molecular response. This comprehensive approach ensures that clinicians can identify patients who need the graft-versus-leukemia effect of a transplant while sparing others from unnecessary toxicity.

Cohort Characteristics and Intention-to-Treat Distribution

The prospective trial, registered at ClinicalTrials.gov as NCT04179929, analyzed outcomes in a cohort of 436 adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. The researchers utilized a protocol that integrated centrally assessed genetics with measurable residual disease. This centralized assessment ensured that treatment decisions were based on standardized molecular and cytogenetic data rather than local laboratory variations, which is crucial for reproducible clinical decision-making. The study population had a median age of 39 years, with a range spanning from 18 to 60 years, representing a broad cross-section of the adult patient population typically seen in practice. Of the 436 participants, the majority presented with B-lineage acute lymphoblastic leukemia (332 patients), while the remaining 104 patients were diagnosed with T-lineage acute lymphoblastic leukemia. By applying the integrated criteria of genetic risk and early molecular response, the investigators determined the optimal consolidation strategy for each patient. Based on the intention-to-treat analysis, which evaluates patients according to their initially assigned treatment group, the study categorized the 400 non-early T-cell precursor patients into two distinct pathways. A total of 243 non-early T-cell precursor patients (61%) were assigned to allogeneic hematopoietic stem cell transplant due to high-risk genetic features or inadequate molecular response. Conversely, 157 non-early T-cell precursor patients (39%) were assigned to receive consolidation chemotherapy, identifying a substantial subgroup of adults who may achieve durable remissions without the need for an intensive transplant procedure.

Survival Outcomes and the Impact of Genetic Risk

The implementation of this risk-stratified protocol resulted in a 3-year overall survival probability of 64% (95% CI, 58% to 69%) for the entire cohort of 436 patients. Within the specific subgroup of patients diagnosed with early T-cell precursor acute lymphoblastic leukemia, a notoriously difficult-to-treat variant, the 3-year overall survival probability was 61% (95% CI, 37% to 79%). These figures provide a clear benchmark for the efficacy of integrating genetic markers with early molecular responses to guide transplant decisions in a diverse adult population. Most importantly, the study findings emphasize that baseline genetic risk remains a critical determinant of long-term outcomes, even when patients achieve deep molecular remissions. For the 109 patients who achieved a complete remission and reached an end-of-induction measurable residual disease level of less than 0.01% without high genetic risk, the 3-year overall survival probability was 81% (95% CI, 70% to 89%). This high survival rate suggests that this specific subgroup can safely avoid the morbidity and mortality associated with transplantation. In stark contrast, the prognosis was significantly worse for the 64 patients who were measurable residual disease-negative but possessed high genetic risk features, as their 3-year overall survival probability dropped to 50% (95% CI, 34% to 63%). For practicing hematologists and oncologists, this disparity highlights a crucial clinical lesson: achieving a molecularly undetectable state does not fully mitigate the biological hazards of high-risk genetics. These findings reinforce the necessity of transplantation for genetically high-risk individuals, regardless of how well they respond to initial induction therapy.

Study Info

Genetics and MRD for therapy allocation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia

Josep‐María Ribera, Anna Torrent, Mireia Morgades, Susana Bárrena, et al.

Journal Blood

Published May 04, 2026